Schizophrenia Clinical Trial
Official title:
Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients
This clinical trial tests the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy for patients diagnosed with schizophrenia or schizoaffective disorder within a forensic hospital. It is hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance, real world functioning, symptoms, violence risk and benefit more from additional psychosocial treatment programmes over time relative to patients receiving treatment as usual. Furthermore it is hypothesised that it will be feasible to carry out such a study and that patients will report high rates of satisfaction with cognitive remediation therapy. Finally it is hypothesised that differences on the effectiveness measures will be maintained at 6 month follow up after the end of treatment.
This is a single centre randomised clinical trial to evaluate the feasibility, effectiveness
and patient satisfaction with cognitive remediation therapy within a secure forensic setting
for patients diagnosed with schizophrenia or schizoaffective disorder.
The feasibility of the intervention will be assessed using key indicators such as rate of
enrolment, retention of patients in the trial, blinding effectiveness, and completion rate of
the primary outcome measure. The effectiveness of the intervention will be assessed using the
MATRICS consensus cognitive battery, symptoms (PANSS and CAINS) and real world functioning
(SOFAS: Social and occupational functioning assessment scale). The effect of cognitive
remediation on violence risk (HCR-20), programme completion and recovery (Dundrum 3 & 4) will
also be examined, where programme completion is a measure of attainments from participating
in additional psychosocial interventions and recovery is a measure of stability of mental
state.
Patient satisfaction with cognitive remediation therapy will be assessed using a consumer
constructed interview developed by Rose et al (2008) and administered by a social worker not
involved in the delivery of cognitive remediation.
The trial will take place at the Republic of Ireland's Central Mental Hospital (CMH). The CMH
is the only secure forensic psychiatric hospital for the Republic of Ireland, a population of
4.6 million. CMH provides specialised care for adults who have a mental disorder and are at
risk of harming themselves or others.
After a baseline assessment to ensure eligibility and to obtain consent, an estimated 60
patients will be randomised to receive fourteen weeks of cognitive remediation versus
treatment as usual. Patients who receive treatment as usual will be offered cognitive
remediation upon completion of the study. Patients allocated to cognitive remediation will
receive three individual sessions of cognitive remediation a week and one group session,
fifty-six sessions in total The focus of the group session is to normalise cognitive
difficulties that patients may be experiencing, to receive support and to help generalise
gains. The primary outcome measure the MATRICS composite score and secondary outcome measures
to assess real world functioning, symptoms, violence risk, programme completion and recovery
will be administered at baseline, the end of treatment and at six month follow up. Secondary
measures will also include feasibility outcomes and patient satisfaction with cognitive
remediation therapy. All evaluators of the effectiveness measures will be blind to
participant treatment condition at the time of assessment.
The cognitive remediation therapy is a principle driven intervention consisting of nine
treatment principles: Principle 1 refers to relationship building, Principle 2 refers to
collaborative goal setting, Principle 3 involves the session structure, Principle 4 concerns
the content of the sessions, Principle 5, concerns the pacing of sessions, Principle 6
involves scaffolding and errorless learning, Principle 7 refers to meta-cognitive strategies,
Principle 8 involves generalisation of gains, finally Principle 9 refers to managing
ambivalence. The actual therapy will involve the use of a combination on pen, paper and
computerised materials to stimulate patient's cognitive capacity and to provide them with the
opportunity to apply meta-cognitive strategies.
The investigators hypothesise that it is feasible to carry out a randomised controlled trial
within a single centre forensic setting and that patients will report high rates of
satisfaction with cognitive remediation. It is also hypothesised that patients receiving
cognitive remediation therapy will have an improvement in cognitive performance (the primary
outcome measure), real world functioning, symptoms and violence risk over time relative to
patients receiving treatment as usual; specifically that there will be a treatment by time
interaction. Furthermore it is hypothesised that these differences will be maintained at six
month follow up after the end of treatment.
In addition it is hypothesised that patients receiving cognitive remediation will show an
improvement over time on the Dundrum programme completion and recovery scales compared to
those receiving treatment as usual.
While meta-analytic reviews have demonstrated that cognitive remediation therapy has a
beneficial effect on the cognitive deficits experienced by patients with schizophrenia (Wykes
et al 2011), to the best of our knowledge there has been no study with forensic mental health
patients. The current study will help answer whether it is feasible to deliver cognitive
remediation within a forensic mental health setting and whether it is acceptable to patients.
The study aims to contribute to the evidence base for psychological interventions within a
forensic setting and to answer the question as to whether cognitive remediation has a
beneficial effect and if it does whether this effect is maintained over time.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |